Most Read Articles
Roshini Claire Anthony, 6 days ago

The combination of nivolumab and platinum chemotherapy in the neoadjuvant setting improved pathological complete response (pCR) in patients with resectable non-small cell lung cancer (NSCLC), according to results of the phase III CheckMate-816 trial.

Elaine Soliven, 30 Apr 2021
Maintenance treatment with fuzuloparib resulted in significantly improved progression-free survival (PFS) in patients with platinum-sensitive recurrent ovarian cancer, according to a study presented at SGO 2021.
31 Mar 2021
At the recent webinar entitled Pik Me Up: Mutation Matters, Consultant Medical Oncologist Dr Senthil Rajappa discussed the role of PI3Kα-specific inhibitor alpelisib (TREZILENT®, Novartis) in managing patients with HR+/HER2- aBC/MBC and PIK3CA mutations while Senior Consultant Pathologist Professor Dr Pathmanathan Rajadurai explained the process of detecting PIK3CA mutations in patients.
Dr Margaret Shi, 6 days ago

The colony-stimulating factor 1 receptor (CSF-1R) inhibitor pexidartinib is an effective long-term treatment option for adult patients with advanced tenosynovial giant cell tumour (TGCT), but adverse events (AEs), especially liver toxicities, need to be closely monitored. While off-label use of imatinib may be considered in advanced TGCT, development of future-generation CSF-1R inhibitors with an improved AE profile is highly awaited.

Narrow resection margins not linked to mortality, recurrence in Merkel cell carcinoma

06 Apr 2021

Excision with narrow margins does not predict mortality or recurrence in patients with Merkel cell carcinoma, results of a study have shown. Residual tumour, found primarily on deep surgical margins, is independently associated with prognosis.

“Wide local excision constitutes the standard of care for Merkel cell carcinoma, but the optimal margin width remains controversial,” the investigators said.

To assess whether narrow margins (0.5–1 cm) were associated with outcome, the investigators recruited 214 patients from a retrospective French multicentric cohort and had had excision of primary tumour with minimum lateral margins of 0.5 cm. Multivariate regression was used to assess factors associated with mortality and recurrence.

Of the patients, 58 (27.1 percent) had undergone excision with narrow margins (0.5–1 cm) relative to 156 (72.9 percent) with wide margins (>1 cm). Cancer-specific survival was similar between patients with narrow margins and those with wide margins during a median follow-up of 50.7 months (5-year specific survival rate: 76.8 percent, 95 percent confidence interval [CI], 61.7–91.9 percent vs 76.2 percent, 95 percent CI, 68.8–83.6 percent, respectively).

In addition, no significant between-group differences were observed in overall survival, any recurrence-free survival, and local recurrence-free survival.

Of note, cancer-specific mortality correlated with age, male sex, American Joint Committee of Cancer stage III, and presence of positive margins.

The study was limited by its retrospective design and the heterogeneous baseline characteristics between groups.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 6 days ago

The combination of nivolumab and platinum chemotherapy in the neoadjuvant setting improved pathological complete response (pCR) in patients with resectable non-small cell lung cancer (NSCLC), according to results of the phase III CheckMate-816 trial.

Elaine Soliven, 30 Apr 2021
Maintenance treatment with fuzuloparib resulted in significantly improved progression-free survival (PFS) in patients with platinum-sensitive recurrent ovarian cancer, according to a study presented at SGO 2021.
31 Mar 2021
At the recent webinar entitled Pik Me Up: Mutation Matters, Consultant Medical Oncologist Dr Senthil Rajappa discussed the role of PI3Kα-specific inhibitor alpelisib (TREZILENT®, Novartis) in managing patients with HR+/HER2- aBC/MBC and PIK3CA mutations while Senior Consultant Pathologist Professor Dr Pathmanathan Rajadurai explained the process of detecting PIK3CA mutations in patients.
Dr Margaret Shi, 6 days ago

The colony-stimulating factor 1 receptor (CSF-1R) inhibitor pexidartinib is an effective long-term treatment option for adult patients with advanced tenosynovial giant cell tumour (TGCT), but adverse events (AEs), especially liver toxicities, need to be closely monitored. While off-label use of imatinib may be considered in advanced TGCT, development of future-generation CSF-1R inhibitors with an improved AE profile is highly awaited.